Bashan Dror reported PLX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001781450-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Sep 3, 2026

Published

Sep 4, 2026

Ingested by INSIDER

Nov 5, 02:18 UTC

Last re-read

Nov 5, 02:18 UTC

Extracted facts

Filer

Bashan Dror

Role

Director, PRESIDENT AND CEO

Transaction

Grant or awardAs filed: “A”

Asset

Protalix BioTherapeutics, Inc. — Restricted Stock Units

Ticker

PLX

Shares

160.0K

Price per share

$0

Execution date (reported)

Sep 3, 2026

Owned after transaction

160.0K shares

Days from execution to publication

1

What this establishes

Bashan Dror filed this Form 4 reporting a grant or award of PLX on Sep 3, 2026. It became public on Sep 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director, PRESIDENT AND CEO

Bashan Drorcik:0001781450

Issuer

Protalix BioTherapeutics, Inc.cik:0001006281

Revision history · 0

No field has changed since this record was first ingested.